Clinical trials
Metabolic Associated Fatty Liver Disease clinical trials
Below are recruiting metabolic associated fatty liver disease clinical trials, each written for real people, not researchers. We’re tracking 70 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06274788Recruiting
Safety study of long-term Omegaven for liver problems from IV nutrition
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
Fountain Valley, CaliforniaAges 1 day–17 years - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT05330923Recruiting
HIV and fatty liver check-in study with ultrasound follow-up
This study follows people with HIV who also have fatty liver disease and checks their health over time. It may help by improving monitoring and care planning, especially using ultrasound scans and regular follow-up.
Beijing, Beijing MunicipalityAges Any age - NCT05332613Recruiting
Diet and meal timing study for fatty liver
This study looks at whether changing when and how people eat can improve fatty liver disease caused by metabolic problems. It uses MRI to measure liver fat and compares outcomes while participants follow a structured eating schedule.
New York, New YorkAges 18–65 - NCT04873258Recruiting
Test a non-invasive tool to screen for fat-related liver disease
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
London, LondonAges 18–80 - NCT07013916Recruiting
Fructose and liver health in fatty liver disease
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
LondonAges 45–65 - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT06453915RecruitingEarly Phase 1
Brain PET scan for inflammation in fatty liver disease
This study uses a special PET scan to look for inflammation in the brain related to fatty liver disease. It may help researchers understand how liver health affects brain function.
Sacramento, CaliforniaAges 18 years+ - NCT06354088RecruitingPhase 1
Study of alpelisib for insulin resistance
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
New York, New YorkAges 18–70 - NCT07145151RecruitingPhase 2
Studying UBT251 for MASH liver disease
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Beijing, Beijing MunicipalityAges 18–75 - NCT06937749RecruitingPhase 2
Study of IBI362 for liver scarring from MASH
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05945537RecruitingPhase 1
Testing INI-822 in healthy people and those with MASH
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
Camperdown, New South WalesAges 18–70 - NCT07820644Recruiting
Liver cancer risk prediction in chronic liver disease
This study aims to predict the risk of developing liver cancer in people with chronic liver conditions such as hepatitis B or C, cirrhosis, or fatty liver disease. By participating, you may help researchers improve early detection and prevention strategies for liver cancer.
Shenzhen, GuangdongAges 18–75 - NCT07463287Recruiting
Fatty liver and colorectal polyp risk study
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT05984745RecruitingPhase 2
CoQ10 for fatty liver linked to metabolic issues
This study tests if CoQ10 (a natural supplement) can improve liver health in people with metabolic dysfunction-associated fatty liver disease (MAFLD). It may help if you have a fatty liver and related metabolic issues like high blood pressure or diabetes.
CairoAges 18–80 - NCT06953505Recruiting
At-home ammonia monitoring for inherited metabolic disorders
This trial tests a device for measuring ammonia levels at home in people with rare metabolic conditions that cause high ammonia. It aims to make monitoring easier and more convenient for patients.
Portland, OregonAges 12 years+ - NCT07581951RecruitingPhase 3
Study of HSK31679 for people with MASH (liver scarring)
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Metabolic Associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metabolic associated fatty liver disease?
- Yes. Clin2 currently lists 70 recruiting metabolic associated fatty liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metabolic associated fatty liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metabolic associated fatty liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metabolic Dysfunction-associated Fatty Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Associated Steatotic Liver Disease
- Metabolic Dysfunction-Associated Liver Disease
- Non-Alcoholic Fatty Liver Disease
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Fatty Liver
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.